Jason Carroll (researcher)

Jason Carroll
FMedSci
Alma materUniversity of Melbourne
AwardsFellow of the Academy of Medical Sciences
Scientific career
InstitutionsCancer Research UK Cambridge Institute, University of Cambridge
Websitewww.cruk.cam.ac.uk/research-groups/carroll-group

Professor Jason Carroll FMedSci is a British medical researcher serving as Deputy Director and Senior Group Leader at the Cancer Research UK Cambridge Institute, University of Cambridge[1]. He is a Professor of Molecular Oncology assigned to the Department of Oncology[2], co-lead of the Breast Cancer Programme at the Cancer Research UK Cambridge Centre[3] and a Fellow of Clare College, Cambridge.[4] He was Founder and Chief Scientific Officer of Azeria Therapeutics from 2017-2020.[5]

Education

Carroll completed his B.Sc Hons in Molecular Biology at the University of Melbourne before undertaking his PhD in Cancer Research at The Garvan Institute and University of New South Wales.[5] He completed his postdoctoral training with Professor Myles Brown from 2002-2007 at Dana-Farber Cancer Institute, Harvard Medical School. [6][7]

Career

Carroll's research uses molecular, genomic and proteomic approaches to understand how the Estrogen Receptor causes gene transcription and how this contributes to breast cancer progression.[8]

With Prof Myles Brown and Dr Shirley Liu, Carroll developed one of the first chromosome-wide and then genome-wide transcription factor mapping approaches, which was used to discover that Estrogen Receptor (ER) regulates genes from distal enhancers rather than promoter regions. This work also led to the discovery that FOXA1 is a pioneer factor for ER[6][7] in breast cancer and subsequent work identified the role of FOXA1 in treatment resistance[9].

He developed the first approaches for mapping transcription factors by ChIP-seq in primary tumour tissue[10]. He also developed the proteomic method RIME (Rapid Immunoprecipitation Mass Spectrometry of Endogenous proteins) for unbiased discovery of protein interactomes, which was used to discover an interaction between ER and Progesterone Receptor (PR), revealing the concept that PR activation could reprogram and inhibit ER activity in breast cancer. This fundamental discovery was validated in the PIONEER Phase II window-of-opportunity clinical trial, which showed that inclusion of a PR-targeted drug could improve anti-tumour activity in primary breast cancer patients.[11]

Carroll also discovered the role of pioneer factor FOXA1 in breast cancer, demonstrating that it is key in enabling the estrogen receptor to interact with the DNA in breast cancer cells, switching on genes that trigger unchecked growth.[12][13] In 2015, Carroll's work uncovered why women who have high levels of both the estrogen and progesterone receptors have a better chance of breast cancer survival, and found that adding progesterone at the same time as tamoxifen slows tumour growth in the laboratory.[14][15][16]

In 2017, Carroll founded Azeria Therapeutics Limited to develop treatments for hormone resistant breast and prostate cancer, building on his work with pioneer factor FOXA1.[5][17][18]

Awards and honours

References

  1. ^ "Carroll Group". Cancer Research UK Cambridge Institute. Retrieved 2019-09-03.
  2. ^ "Institute Group Leaders awarded promotions in the University". Cancer Research UK Cambridge Institute. 2019-07-24. Retrieved 2019-09-03.
  3. ^ "Breast Cancer Virtual Institute". crukcambridgecentre.org.uk. Retrieved 2025-12-16.
  4. ^ "Fellows of Clare College - Clare College Cambridge". www.clare.cam.ac.uk. Archived from the original on 2020-08-08. Retrieved 2019-09-03.
  5. ^ a b c "Developing pioneering cancer treatments". Azeria Therapeutics. Retrieved 2019-09-03.
  6. ^ a b Carroll, Jason S.; Liu, X. Shirley; Brodsky, Alexander S.; Li, Wei; Meyer, Clifford A.; Szary, Anna J.; Eeckhoute, Jerome; Shao, Wenlin; Hestermann, Eli V.; Geistlinger, Timothy R.; Fox, Edward A.; Silver, Pamela A.; Brown, Myles (July 2005). "Chromosome-Wide Mapping of Estrogen Receptor Binding Reveals Long-Range Regulation Requiring the Forkhead Protein FoxA1". Cell. 122 (1): 33–43. doi:10.1016/j.cell.2005.05.008.
  7. ^ a b Carroll, Jason S; Meyer, Clifford A; Song, Jun; Li, Wei; Geistlinger, Timothy R; Eeckhoute, Jérôme; Brodsky, Alexander S; Keeton, Erika Krasnickas; Fertuck, Kirsten C; Hall, Giles F; Wang, Qianben; Bekiranov, Stefan; Sementchenko, Victor; Fox, Edward A; Silver, Pamela A (November 2006). "Genome-wide analysis of estrogen receptor binding sites". Nature Genetics. 38 (11): 1289–1297. doi:10.1038/ng1901. ISSN 1061-4036.
  8. ^ "Jason Carroll - Google Scholar Citations". scholar.google.com. Retrieved 2019-09-03.
  9. ^ Hurtado, Antoni; Holmes, Kelly A; Ross-Innes, Caryn S; Schmidt, Dominic; Carroll, Jason S (January 2011). "FOXA1 is a key determinant of estrogen receptor function and endocrine response". Nature Genetics. 43 (1): 27–33. doi:10.1038/ng.730. ISSN 1061-4036. PMC 3024537. PMID 21151129.
  10. ^ Ross-Innes, Caryn S.; Stark, Rory; Teschendorff, Andrew E.; Holmes, Kelly A.; Ali, H. Raza; Dunning, Mark J.; Brown, Gordon D.; Gojis, Ondrej; Ellis, Ian O.; Green, Andrew R.; Ali, Simak; Chin, Suet-Feung; Palmieri, Carlo; Caldas, Carlos; Carroll, Jason S. (January 2012). "Differential oestrogen receptor binding is associated with clinical outcome in breast cancer". Nature. 481 (7381): 389–393. doi:10.1038/nature10730. ISSN 0028-0836. PMC 3272464. PMID 22217937.
  11. ^ Burrell, Rebecca; Kumar, Sanjeev; McIntosh, Stuart; Pitsinis, Vassilis; King, Polly; Elsberger, Beatrix; Govindarajulu, Sasirekha; Satherley, Lucy; Hadad, Sirwan; Schmid, Peter; Abraham, Jean; Agrawal, Amit; Benson, John; Cheeseman, Danya; Chernukhin, Igor (2024-05-02). "Abstract PS15-06: Results of the window-of-opportunity PIONEER trial evaluating addition of the progesterone receptor (PR) agonist megestrol to letrozole for early stage estrogen receptor (ER) positive breast cancer: exploiting ER-PR interaction". Cancer Research. 84 (9_Supplement): PS15–06-PS15-06. doi:10.1158/1538-7445.SABCS23-PS15-06. ISSN 1538-7445. Archived from the original on 2024-06-14.
  12. ^ Carroll, Jason S.; Schmidt, Dominic; Ross-Innes, Caryn S.; Holmes, Kelly A.; Hurtado, Antoni (January 2011). "FOXA1 is a key determinant of estrogen receptor function and endocrine response". Nature Genetics. 43 (1): 27–33. doi:10.1038/ng.730. ISSN 1546-1718. PMC 3024537. PMID 21151129.
  13. ^ "Single gene essential for oestrogen response in breast cancer". Cancer Research UK. 2013-12-05. Retrieved 2019-09-03.
  14. ^ Sample, Ian (2015-07-08). "Breast cancer hope as hormone shown to slow tumour growth". The Guardian. ISSN 0261-3077. Retrieved 2019-09-03.
  15. ^ "Solving a breast cancer mystery – why do 'double-positive' women do better?". Cancer Research UK - Science blog. 8 July 2015. Retrieved 2019-09-03.
  16. ^ Carroll, Jason S.; Tilley, Wayne D.; Caldas, Carlos; Stingl, John; Perou, Charles M.; Launchbury, Rosalind; Silva, Grace; Robinson, Jessica L. L.; D’Santos, Clive (July 2015). "Progesterone receptor modulates ERα action in breast cancer". Nature. 523 (7560): 313–317. Bibcode:2015Natur.523..313M. doi:10.1038/nature14583. ISSN 1476-4687. PMC 4650274. PMID 26153859.
  17. ^ "Azeria Therapeutics". www.businessweekly.co.uk. Retrieved 2019-09-03.
  18. ^ Therapeutics, Azeria. "Azeria Therapeutics, the World's First Pioneer Factor Drug Discovery Company, Announces Series A Investment from Sixth Element Capital". www.prnewswire.co.uk. Retrieved 2019-09-03.
  19. ^ "BACR/AstraZeneca Young Scientist Frank Rose Award". www.bacr.org.uk. Retrieved 2019-09-03.
  20. ^ adit. "Twenty-one group leaders join network of EMBO Young Investigators". EMBO. Archived from the original on 2019-09-03. Retrieved 2019-09-03.
  21. ^ "Future Leaders in Cancer Research Prize". Cancer Research UK. 2015-10-28. Retrieved 2019-09-03.
  22. ^ "Jason Carroll receives AACR Outstanding Investigator Award Scholarship". Cancer Research UK Cambridge Institute. 2013-09-26. Retrieved 2019-09-03.
  23. ^ "AACR Outstanding Investigator Award for Breast Cancer Research, supported by The Breast Cancer Research Foundation". www.aacr.org. Archived from the original on 2019-09-03. Retrieved 2019-09-03.
  24. ^ "Louis-Jeantet Young Investigator Career Award". Jeantet. 2017-09-17. Retrieved 2019-09-03.
  25. ^ "Find people in the EMBO Communities". people.embo.org. Retrieved 2019-09-03.
  26. ^ "The Academy of Medical Sciences announces new Fellows for 2017". University of Cambridge. 2017-05-08. Retrieved 2019-09-03.
  27. ^ "Dr Jason Carroll". acmedsci.ac.uk. Retrieved 2019-09-03.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.